Figure 7.

Analysis of survival and cumulative risk of relapse and early death for final low-risk patients without ETV6-RUNX1 positivity or hyperdiploidy ALL and didn’t meet the criteria for the second dose of daunorubicin.

Analysis of survival and cumulative risk of relapse and early death for final low-risk patients without ETV6-RUNX1 positivity or hyperdiploidy ALL and didn’t meet the criteria for the second dose of daunorubicin.